ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

Core Insights - ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [2][12] - The company reported a net loss of approximately $2.3 million for Q1 2025, an improvement of 20.2% compared to a net loss of $2.8 million in Q1 2024 [8][20] - ZyVersa anticipates that its cash of $1.6 million as of March 31, 2025, will be sufficient for month-to-month operations but will require additional financing for ongoing operations and clinical activities [9] Pipeline Update - The Cholesterol Efflux Mediator VAR 200 is set to begin a Phase 2a clinical trial for diabetic kidney disease (DKD) by the end of June 2025, with the goal of obtaining proof-of-concept before a larger Phase 2a/b trial for FSGS [4][5] - The Inflammasome ASC Inhibitor IC 100 is preparing for an Investigational New Drug (IND) application in the second half of 2025, with a Phase 1 trial expected to start in healthy overweight subjects at risk of cardiometabolic diseases in early 2026 [5][7] - Recent data indicates that IC 100 effectively blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation, which are critical factors in neurodegeneration and Parkinson's disease [5][6] Financial Performance - Research and development expenses for Q1 2025 were $259 thousand, a decrease of 49.5% from $512 thousand in Q1 2024, attributed to lower manufacturing costs and fewer consultant engagements [10] - General and administrative expenses were $1.9 million for Q1 2025, down 18.5% from $2.3 million in Q1 2024, primarily due to reduced stock-based compensation and lower marketing expenses [11] - The total operating expenses for Q1 2025 were $2.1 million, compared to $2.8 million in Q1 2024, reflecting a significant reduction in costs [20]